{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:25Z","timestamp":1787169925349,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>ABSTRACT<\/jats:title>\n                    <jats:p>India is well known as the diabetes \u201ccapital\u201d of the world but now it is also becoming the mucormycosis \u201ccapital\u201d of the world. Indian Council of Medical Research has formed an \u201cEvidence-Based Advisory in The Time of COVID-19 on Screening, Diagnosis, and Management of Mucormycosis.\u201d As per this advisory, an oral and maxillofacial surgeon forms an integral part of the team dedicated to fight this epidemic of mucormycosis. Also, there are other fungal infections such as aspergillosis which are getting reported in these patients affecting the paranasal sinuses and the jaws. Aggressive surgical debridement and a thorough knowledge of anti-fungal therapy are must in treating these fungal infections. The aim of this article is to give an overview on the available anti-fungal therapy required to manage the ever-increasing rise in fungal infections faced by maxillofacial surgeons in post-COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njms.njms_412_21","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:38:02Z","timestamp":1681097882000},"page":"330-336","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anti-fungal therapy"],"prefix":"10.4103","volume":"13","author":[{"given":"Abhay","family":"Datarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bhawalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Daware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damyanti","family":"Walkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240908","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi (Basel"},{"key":"R3-3-20240908","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1017\/S0022215121000992","article-title":"Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum","volume":"135","author":"Sharma","year":"2021","journal-title":"J Laryngol Otol"},{"key":"R5-3-20240908","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof2040026","article-title":"New horizons in antifungal therapy?","volume":"2","author":"Pianalto","year":"2016","journal-title":"J Fungi"},{"key":"R7-3-20240908","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"R8-3-20240908","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1055\/s-2007-985641","article-title":"Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial","volume":"132","author":"Rieger","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"R9-3-20240908","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1439-0507.2006.01295.x","article-title":"A new, broad-spectrum azole antifungal: Posaconazole\u2013mechanisms of action and resistance, spectrum of activity","volume":"49","author":"Hof","year":"2006","journal-title":"Mycoses"},{"key":"R10-3-20240908","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IDR.S118892","article-title":"Fluconazole resistance in Candida species: A current perspective","volume":"10","author":"Berkow","year":"2017","journal-title":"Infect Drug Resist"},{"key":"R11-3-20240908","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole: An update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R12-3-20240908","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/17425250903463878","article-title":"Pharmacology and clinical use of voriconazole","volume":"6","author":"Thompson","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R13-3-20240908","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2146\/ajhp070532","article-title":"Posaconazole: A new oral antifungal agent with an expanded spectrum of activity","volume":"66","author":"Morris","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R14-3-20240908","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1182\/blood-2018-99-111727","article-title":"Isavuconazole (ISAV) as primary anti-fungal prophylaxis in acute myeloid leukemia or myelodysplastic syndrome: An open-label, prospective study","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"key":"R15-3-20240908","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol"},{"key":"R16-3-20240908","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1128\/AAC.49.7.2851-2856.2005","article-title":"Cryptococcus neoformans resistance to echinocandins: (1, 3) \u03b2-glucan synthase activity is sensitive to echinocandins","volume":"49","author":"Maligie","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-3-20240908","doi-asserted-by":"crossref","first-page":"e2870","DOI":"10.1371\/journal.pone.0002870","article-title":"Major role for amphotericin B\u2013flucytosine combination in severe cryptococcosis","volume":"3","author":"Dromer","year":"2008","journal-title":"PloS One"}],"container-title":["National Journal of Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njms.njms_412_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:05Z","timestamp":1787166905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njms.njms_412_21"}},"subtitle":["An overview for maxillofacial surgeons in post-covid-19 fungal infections"],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/njms.njms_412_21","relation":{},"ISSN":["0975-5950"],"issn-type":[{"value":"0975-5950","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}